<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825512</url>
  </required_header>
  <id_info>
    <org_study_id>DEEP-2</org_study_id>
    <nct_id>NCT01825512</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients</brief_title>
  <official_title>Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorzio per Valutazioni Biologiche e Farmacologiche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorzio per Valutazioni Biologiche e Farmacologiche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate&#xD;
      efficacy and safety of a 12-months treatment with deferiprone (DFP) at dose of 75-100&#xD;
      mg/kg/day versus deferasirox (DFX) at dose of 20-40 mg/kg/day in paediatric patients (1 month&#xD;
      &lt; 18 years old) affected by hereditary haemoglobinopathies and requiring frequent&#xD;
      transfusions and chelation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemoglobinopathies are a group of inherited disorders characterized by structural variations&#xD;
      of the haemoglobin molecule. Most of the patients affected require for survival chronic red&#xD;
      blood cells transfusions to overcome ineffective erythropoiesis. Unfortunately, all&#xD;
      chronically transfused patients become clinically iron overloaded as there is no&#xD;
      physiological mechanism for the removal of iron from the body. The pathologic changes and&#xD;
      clinical manifestations associated to chronic iron overload are common among all&#xD;
      transfusional iron-overload patients, albeit best documented in patients with&#xD;
      beta-thalassemia major. The recommended treatment consists in regular blood transfusions&#xD;
      combined with chelating therapy to remove the harmful iron accumulation in the body.&#xD;
&#xD;
      Currently, in the clinical practice particularly in children and adolescents, the criteria&#xD;
      leading to the choice of the chelating agent include also the adherence to therapy, thus&#xD;
      favouring the use of oral chelators (Ceci A et al., 2011) DFP (Deferiprone) was the first&#xD;
      oral chelator authorised in Europe in 1999 as second line treatment for the treatment of iron&#xD;
      overload in patients with thalassaemia major when DFO (Deferoxamine) is contraindicated or&#xD;
      inadequate. However, despite a wide experience of DFP with iron overloaded (specifically&#xD;
      thalassaemic )patients, limited data are available for younger children. For this reason the&#xD;
      need for additional data in younger children is expressively included in the 2009 PDCO&#xD;
      (Paediatric Committee) Priority List.&#xD;
&#xD;
      The purpose of this study is to assess the non-inferiority of DFP compared to DFX&#xD;
      (deferasirox)in paediatric patients affected by hereditary haemoglobinopathies requiring&#xD;
      chronic transfusions and chelation. Non inferiority will be established in terms of&#xD;
      percentage of patients successfully chelated, as assessed by serum ferritin levels (in all&#xD;
      patients) and cardiac MRI T2* (in patients above 10 years of age able to have an MRI scan&#xD;
      without sedation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2014</start_date>
  <completion_date type="Actual">September 21, 2017</completion_date>
  <primary_completion_date type="Actual">September 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Successfully Chelated Patients</measure>
    <time_frame>at baseline and after 12 months</time_frame>
    <description>Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver MRI</measure>
    <time_frame>at baseline and after 12 months</time_frame>
    <description>Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI T2*</measure>
    <time_frame>at baseline and after 12 months</time_frame>
    <description>Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin Level</measure>
    <time_frame>at baseline and after 12 months</time_frame>
    <description>Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">435</enrollment>
  <condition>Chronic Iron Overload</condition>
  <arm_group>
    <arm_group_label>Deferiprone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75-100 mg/kg/day seven days per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferasirox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 to 40 mg/kg/day seven days per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>Deferiprone 80 mg/mL oral solution</description>
    <arm_group_label>Deferiprone</arm_group_label>
    <other_name>DFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <description>Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
    <arm_group_label>Deferasirox</arm_group_label>
    <other_name>DFX</other_name>
    <other_name>ATC Code:V03AC03</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both genders aged from 1 month up to less than 18 years at the time of&#xD;
             enrolment&#xD;
&#xD;
          -  Patients affected by any hereditary haemoglobinopathy requiring chronic transfusion&#xD;
             therapy and chelation, including but not limited to thalassemia syndromes and sickle&#xD;
             cell disease&#xD;
&#xD;
          -  Patients on current treatment with deferoxamine (DFO) or DFX or DFP in a chronic&#xD;
             transfusion program receiving at least 150 mL/kg/year of packed red blood cells&#xD;
             (corresponding approximately to 12 transfusions);&#xD;
&#xD;
          -  For patients naïve to chelation treatment: patients that have received at least 150&#xD;
             mL/kg of packed red blood cells (corresponding to approximately 12 transfusions) in a&#xD;
             chronic transfusion program and with serum ferritin levels ≥ 800 ng/mL;&#xD;
&#xD;
          -  Until availability of results from the PK Study (Study DEEP-1, EudraCT n.&#xD;
             2012-000658-67) for patients aged from 1 month to less than 6 years: known intolerance&#xD;
             or contraindication to DFO;&#xD;
&#xD;
          -  Written informed consent and patient's informed assent, relating to his/her&#xD;
             comprehension abilities and level of maturity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with intolerance or known contraindication to either DFP or DFX&#xD;
&#xD;
          -  Patients receiving DFX at a dose &gt; 40 mg/kg/day or DFP at a dose &gt; 100 mg/kg/day at&#xD;
             screening&#xD;
&#xD;
          -  Platelet count &lt;100.000/mm3 during the run-in phase&#xD;
&#xD;
          -  Absolute neutrophils count &lt;1.500/mm3 during the run-in phase&#xD;
&#xD;
          -  Hb levels lower than 8g/dL during the run-in phase&#xD;
&#xD;
          -  Evidence of abnormal liver function&#xD;
&#xD;
          -  Iron overload from causes other than transfusional haemosiderosis&#xD;
&#xD;
          -  Severe heart dysfunction secondary to iron overload&#xD;
&#xD;
          -  Serum creatinine level &gt; ULN (Upper Limit of Normal) for age during the run-in phase&#xD;
&#xD;
          -  History of significant medical or psychiatric disorder&#xD;
&#xD;
          -  The patient has received another investigational drug within 30 days prior to this&#xD;
             clinical trial&#xD;
&#xD;
          -  Fever and other signs/symptoms of infection in the 10 days before baseline assessment&#xD;
&#xD;
          -  Concomitant use of trivalent cation-dependent medicinal products such as&#xD;
             aluminium-based antacids&#xD;
&#xD;
          -  Positive test for β-HCG (Human chorionic gonadotropin) and lactating female patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donato Bonifazi, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Consorzio per Valutazioni Biologiche e Farmacologiche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurelio Maggio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedali Riuniti Villa Sofia-Cervello</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital 'Ihsan Çabej'</name>
      <address>
        <city>Lushnjë</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qendra Spitalore Universitare &quot;Nene Tereza&quot; Tirane</name>
      <address>
        <city>Tirana</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical and Public health Services of the Ministry of Health</name>
      <address>
        <city>Nicosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria University Hospital - Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zagazig University Hospitals</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National And Kapodistrian University of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Thalassemia, Ospedale Civile di Lentini</name>
      <address>
        <city>Lentini</city>
        <state>SR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Bari - Facoltà di Medicina</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Cagliari Ospedale Regionale per le Microcitemie</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero &quot;Annunziata&quot;, Centro di Studi della Microcitemia</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;Antonio Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Emoglobinopatie, Ospedale G. Di Cristina</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica Università - ASL 1 D.H per Talassemia</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre National de Greffe de Moelle Osseuse Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Cyprus</country>
    <country>Egypt</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.deepproject.eu/</url>
    <description>official project website</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <results_first_submitted>January 27, 2021</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic iron overload</keyword>
  <keyword>hereditary haemoglobinopathy</keyword>
  <keyword>beta thalassaemia major</keyword>
  <keyword>chelating agents</keyword>
  <keyword>deferiprone</keyword>
  <keyword>deferasirox</keyword>
  <keyword>children</keyword>
  <keyword>paediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT01825512/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Informed consent was collected for 435 patients that were enrolled in the study, however 42 of them were excluded from the study for the following reasons: 17 did not meet inclusion criteria, 5 withdrew the consent and 20 were lost to follow-up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Deferiprone</title>
          <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
        </group>
        <group group_id="P2">
          <title>Deferasirox</title>
          <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Deferiprone</title>
          <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
        </group>
        <group group_id="B2">
          <title>Deferasirox</title>
          <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
            <count group_id="B2" value="197"/>
            <count group_id="B3" value="390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;6 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; or equal to 6 years and &lt;10 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; or equal to 10 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest of Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin America</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyprus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="193"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ferritin level</title>
          <population>The difference is due to missing data at baseline</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="163"/>
                    <count group_id="B2" value="173"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2756" spread="2175"/>
                    <measurement group_id="B2" value="2989" spread="2409"/>
                    <measurement group_id="B3" value="2876" spread="2298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Successfully Chelated Patients</title>
        <description>Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation)</description>
        <time_frame>at baseline and after 12 months</time_frame>
        <population>Per-protocol population 1 (PP1): number of patients for whom the primary composite efficacy endpoint data were available at baseline and after 1 year of treatment (271 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox</title>
            <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Successfully Chelated Patients</title>
          <description>Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation)</description>
          <population>Per-protocol population 1 (PP1): number of patients for whom the primary composite efficacy endpoint data were available at baseline and after 1 year of treatment (271 subjects)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Deferiprone was declared non inferior to Deferasirox if the lower limit of the 95% confidence interval for the difference in the proportion of successful chelation in the two groups is above -12.5%.</non_inferiority_desc>
            <param_type>Treatment success rate</param_type>
            <param_value>-12.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver MRI</title>
        <description>Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline.</description>
        <time_frame>at baseline and after 12 months</time_frame>
        <population>Per-protocol population 3 (PP3): number of patients for whom liver iron concentration were available at baseline and after 1 year of treatment (106 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox</title>
            <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Liver MRI</title>
          <description>Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline.</description>
          <population>Per-protocol population 3 (PP3): number of patients for whom liver iron concentration were available at baseline and after 1 year of treatment (106 subjects)</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.848" spread="0.887"/>
                    <measurement group_id="O2" value="-2.975" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GLM model</non_inferiority_desc>
            <p_value>0.074</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.213</ci_lower_limit>
            <ci_upper_limit>4.468</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac MRI T2*</title>
        <description>Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success.</description>
        <time_frame>at baseline and after 12 months</time_frame>
        <population>Per-protocol population 3 (PP3): number of patients for whom cardiac T2* concentration were available at baseline and after 1 year of treatment (108 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox</title>
            <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac MRI T2*</title>
          <description>Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success.</description>
          <population>Per-protocol population 3 (PP3): number of patients for whom cardiac T2* concentration were available at baseline and after 1 year of treatment (108 subjects)</population>
          <units>milliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.488" spread="1.284"/>
                    <measurement group_id="O2" value="1.121" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GLM Analysis</non_inferiority_desc>
            <p_value>0.717</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.633</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.741</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.085</ci_lower_limit>
            <ci_upper_limit>2.819</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ferritin Level</title>
        <description>Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline.</description>
        <time_frame>at baseline and after 12 months</time_frame>
        <population>Per-protocol population 2 (PP2): number of patients for whom the per-protocol centralised serum ferritin concentration data were available at baseline and after 1 year of treatment (303 subjects, this population was larger than PP1 because PP2 included patients who did not have cardiac T2* data)</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox</title>
            <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Ferritin Level</title>
          <description>Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline.</description>
          <population>Per-protocol population 2 (PP2): number of patients for whom the per-protocol centralised serum ferritin concentration data were available at baseline and after 1 year of treatment (303 subjects, this population was larger than PP1 because PP2 included patients who did not have cardiac T2* data)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-397.583" spread="121.794"/>
                    <measurement group_id="O2" value="-398.184" spread="110.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non inferiority of Deferiprone to Deferasirox is tested considering a non-inferiority margin of 400 ng/mL.</non_inferiority_desc>
            <p_value>0.997</p_value>
            <method>GLM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.601</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>164.734</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-323.580</ci_lower_limit>
            <ci_upper_limit>324.781</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, an average of 1 year for subject</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Deferiprone</title>
          <description>75-100 mg/kg/day seven days per week&#xD;
Deferiprone: Deferiprone 80 mg/mL oral solution</description>
        </group>
        <group group_id="E2">
          <title>Deferasirox</title>
          <description>20 to 40 mg/kg/day seven days per week&#xD;
Deferasirox: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>testicular injury</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="agranulocytosis">agranulocytosis</sub_title>
                <description>agranulocytosis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="neutropenia">neutropenia</sub_title>
                <description>neutropenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="sickle cell anaemia">sickle cell anaemia with crisis subjects affected/exposed</sub_title>
                <description>sickle cell anaemia with crisis subjects affected/exposed</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="diarrhoea">diarrhoea</sub_title>
                <description>diarrhoea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="pyrexia">pyrexia</sub_title>
                <description>pyrexia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="chest pain">chest pain</sub_title>
                <description>chest pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="gait disturbance">gait disturbance</sub_title>
                <description>gait disturbance</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="hypertransaminasaemi">hypertransaminasaemia</sub_title>
                <description>hypertransaminasaemia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="gastroenteritis">gastroenteritis</sub_title>
                <description>gastroenteritis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="meningitis meningoco">meningitis meningococcal</sub_title>
                <description>meningitis meningococcal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="herpangina">herpangina</sub_title>
                <description>herpangina</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="pneumonia">pneumonia</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="subcutaneous abscess">subcutaneous abscess</sub_title>
                <description>subcutaneous abscess</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="urinary tract infect">urinary tract infection</sub_title>
                <description>urinary tract infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="herpes virus infecti">herpes virus infection</sub_title>
                <description>herpes virus infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="impetigo">impetigo</sub_title>
                <description>impetigo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title vocab="upper respiratory tr">upper respiratory tract infection</sub_title>
                <description>upper respiratory tract infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>testicular injury</sub_title>
                <description>testicular injury</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="pain in extremity">pain in extremity</sub_title>
                <description>pain in extremity</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="seizure">seizure</sub_title>
                <description>seizure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="acute kidney injury">acute kidney injury</sub_title>
                <description>acute kidney injury</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title vocab="splenectomy">splenectomy</sub_title>
                <description>splenectomy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>cough</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="193"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="28" subjects_at_risk="193"/>
                <counts group_id="E2" events="56" subjects_affected="32" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="193"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="42" subjects_affected="33" subjects_at_risk="193"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="193"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="193"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>cough</description>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="193"/>
                <counts group_id="E2" events="25" subjects_affected="16" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donato Bonifazi</name_or_title>
      <organization>Consorzio per Valutazioni Biologiche e Farmacologiche</organization>
      <phone>+393936698076</phone>
      <email>ceo@cvbf.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

